Bone cancer pain is a challenge for its not completely clarified mechanism and broad clinical morbidity. Therefore, novel and more effective drugs are urgent needed for improvement of patients' quality of life. Glutamate receptors have been associated with the development of the central sensitization of chronic pain. Inhibition of N-methyl-D-aspartate (NMDA) and metabotropic glutamate (mGlu) receptors can effectively attenuate bone cancer pain, respectively. Herein, our results indicated that levoCorydalmine (l-CDL), a compound from Corydalis yanhusuo W.T. Wang, which has been used in traditional Chinese medicine for pain relief could effectively attenuate bone cancer pain induced by tibia bone cavity tumor cell implantation (TCI) through simultaneously inhibiting the NMDA and mGlu1/5 receptors in rat spinal cord without notable side effects. Both intragastric and intrathecal administration of l-CDL significantly alleviated the mechanical hypersensitivity induced by TCI in rats, and the analgesic effect of l-CDL could be reversed by intrathecal administration of NMDA receptor agonist NMDA and mGlu1/5 receptor agonist DHPG but not AMPA receptor agonist AMPA. l-CDL could also selectively suppress NMDA and DHPG induced rapid rise in Ca 21 oscillations in primary cultures neurons of spinal cord in vitro. The antinociception of l-CDL were partially mediated by the reduced phosphorylation of PKC c and ERK1/2 in spinal cord of TCI rats in a NMDA and mGlu1/5 dependent manner. In conclusion, these results suggested that l-CDL attenuates TCI induced bone cancer pain through simultaneously inhibiting the NMDA and mGlu1/5 receptors and the downstream PKC c, ERK1/2 signaling pathways in the spinal cord.
Pain is one of the most important symptoms for cancer patients. There are about 30-50% cancer patients or 70-90% terminal cancer patients experience significant cancer pain. 1, 2 Common tumors, such as those of the breast, lung and prostate frequently metastasize to multiple bones of the body and induce significant bone pain. Bone cancer pain is the most common source of pain in patients with malignant disease and difficult to treat.
The mechanisms of bone cancer pain are highly complicated. The cancer cells metastasize to the bone and induce peripheral sensitization by sustained releasing algogenic substances, protons and acidosis binding to the receptors in the peripheral nociceptors. 3, 4 The spinal cord can also receive the input from the primary afferent neurons that innervate the tumor-bearing bone to lead to the central sensitization, which is important in the generation and maintenance of bone cancer pain. [3] [4] [5] It is widely accepted that the activation of Nmethyl-D-aspartate (NMDA) receptors, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and group I metabotropic glutamate receptors (mGluR1/5) in the spinal cord promotes the pathology of central sensitization. 6 The NMDA, AMPA and mGlu1/5 receptors have been implicated as mediators of nociceptive plastically 7, 8 and seem to contribute to the excitatory synaptic transmission. Activation of NMDA, AMPA receptors increases the Ca 21 influx and activation of mGlu1/5 receptors promotes the Ca 21 release from intracellular stores to elevate cytosolic Ca 21 . 9 The upregulated intracellular Ca 21 facilitates signal transmission by activating Ca 21 -sensitive proteins, such as protein kinase C g (PKC g) and extracellular signal-regulated kinase (ERK1/ 2) to further enhance the excitability in spinal cord neurons. 8 The NMDA and mGlu1 receptors have been demonstrated to play an important role in the development of bone cancer pain. The spinal NMDA receptor/PKC g signaling pathway in spinal cord has been revealed to promote the development of bone cancer pain. 10 The increased expression of mGlu1 receptors in the central amygdala has also been reported to promote the process of bone cancer pain. 11 Questions remain regarding the exact mechanisms of spinal NMDA and group I mGlu receptors in the bone cancer pain and the option regulation of these receptors with a safe and effective medicine. Many traditional Chinese medicines have been used in China as analgesics for hundreds of years and been proved to be safe in clinical practice. They contain numerous components, but only some display analgesic efficacy. 12 Identify new analgesics from these plants may be a useful strategy for the treatment of bone cancer pain. This study provide the first evidence that levo-Corydalmine (l-CDL), a trace component from Corydalis yanhusuo W.T. Wang could effectively attenuate tibia bone cavity tumor cell implantation (TCI) induced bone cancer pain through co-inhibition of NMDA and mGlu1/5 receptors in rat spinal cord. We further explored the underlying mechanism of the co-inhibition of NMDA and mGlu1/5 receptors by l-CDL in regulating bone cancer pain. Coinhibition of NMDA and mGlu1/5 receptors in the spinal cord may present new opportunities for treatment and management of bone cancer pain.
Material and Methods

Materials
Antiglyceraldehyde 3-phosphate dehydrogenase (GAPDH), deoxyribonuclease and poly-L-lysine, cytosine arabinoside, Lglutamic acid was from Sigma-Aldrich (St. Louis, MO). AntiPhospho-p44/42 MAPK (p-ERK1/2), anti-p44/42 MAPK (ERK1/2) and anti-Phospho-PKC (pan; gamma Thr514; p-PKC g) antibodies were from Cell Signaling Technology (Beverly, MA). Anti-PKC (pan; gamma Thr514; PKC g) antibodies were from Abcam (Cambridge, MA). Secondary antibodies for western blot were from Cell Signaling Technology (Beverly, MA). The fluorescent dye fluo-8 and B-27 were obtained from Invitrogen (Carlsbad, CA). Neurobasal medium and RPMI 1640 medium were from Gibco (Gaithersburg, MD). Trypsin, soybean trypsin inhibitor and heat-inactivated fetal bovine serum were obtained from Atlanta Biologicals (Norcross, GA). NMDA receptor agonist NMDA, a-amino-3-hydroxy-5-methyl-4-isoxazo-lepropionic acid (AMPA) receptor agonist AMPA and group I mGluR1/5 agonist 3,5-dihydroxyphenylglycine (DHPG) were from Tocris Bioscience (Ellisville, MO). All other reagents were purchased from Sigma.
Experimental animals
The study was approved by the Animal Experimentation Ethics Committee of China Pharmaceutical University and performed in accordance with the guidelines of the International Association for the Study of Pain. Adults SpragueDawley female rats weighing 180-220 g (60-80 g used in the expansion of Walker 256 mammary gland carcinoma cells) were purchased from the Experimental Animal Center at Nantong University (Jiangsu Province, China). Rats were housed in a temperature and humidity controlled environment on a 12 hr light/dark cycle for 3-7 days to allow acclimatization and housed five to six per cage. Food and water were provided ad libitum. The rats were randomly allocated to different groups by age and body weight. The rats were anesthetized with pentobarbital (50 mg/kg, i.p.). The behavior test was performed in a blinded manner.
Model of bone cancer pain induced by intratibia inoculation of walker 256 mammary gland carcinoma cells
Walker 256 mammary gland carcinoma cells (5 3 10 6 cells/ ml, 0.5 ml) were implanted intraperitoneally into rats. Five to seven days later, the ascites were extracted and centrifuged at 2000 rpm for 6 min to get the cells. The sediment was washed with 0.01 M phosphate buffered saline (PBS) and recentrifuged for 6 min at 2000 rpm for 2 times and diluted to a density of 1 3 10 5 cells/ll with sterile 0.01 M PBS. The cell suspension was kept on ice until injected into rats. The Walker 256 ascites tumor cells induced bone cancer pain was generated as described before. 13 Briefly, rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and the tibia head of left leg was exposed with minimal damage. Tumor cells (5 ll) were slowly injected into the medullary cavity of the tibia, and in controls 5 ll PBS were injected into the medullary cavity instead. Bone wax was used and held for 3 min to prevent the escape of tumor cells from the bone when the syringe was removed. The injection hole was closed by the dental materials.
Bone radiological detection
To assess the tibia bone destruction by the tumor, bone radiological detection and histology staining were used as described. 13 Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and were exposed to the X-ray source on Day 14 after the surgery. By using the Kodak Digital Radiographer System (Kodak, USA), tibia radiographs were taken from hind limbs (n 5 4/group).
Histology staining
On Day 14 after the surgery, the rats were killed by anesthetized with overdose of pentobarbital. The tibia bones were removed and demineralization in 10% EDTA for 2 weeks. Then the bones were embedded in paraffin and cut into 5 lm thick by the microtome. The sections were stained with hematoxylin and eosin to verify whether the tumors infiltrated the bones (n 5 4/group).
Intrathecal injection procedure
The rat was placed in a prone position and the midpoint between the tips of the iliac crest was located. The intrathecal injections were performed by means of lumbar puncture at the intervertebral space of L4-5 or L5-6 using a stainless steel needle (30 gauge). The proper injection would be accompanied by a tail flick. The injection did not affect the baseline threshold of the rats. ) were used to stimulate the hind paw of rats with logarithmically incremental stiffness and each Von Frey hair was held for about 5 sec. The positive response was defined as a withdrawal of hind paw upon the stimulus. Whenever a positive response to a stimulus occurred, the next lower von Frey hair was applied, and whenever a negative response occurred, the next higher hair was applied. Each rat was tested at least three times and the average of the threshold was measured. The experimenters were blinded to the treatment. 13 The rats were tested for 3 successive days before surgery. To examine the immediate effect of l-CDL on TCI induced bone cancer pain, tests were conducted at 0, 0.5, 2, 4, 8, 24 and 48 hr after a single administration of l-CDL on the 14th postoperative day, and additional tests were conducted at 4 hrs on postoperative days 14 to 20 after l-CDL treatment.
Primary cultures neurons of spinal cord
The spinal cords of the embryo were removed aseptically on Day 13 of gestation. 15 After removing of their meninges, the spinal cords were digested in 0.15% trypsin at 378C for 25 min. The cell suspension was centrifuged at 1000 rpm for 4 min at room temperature. The supernatant was removed with a Pasteur pipette, the cells were resuspended and dissociated by slowly pipetting up-and-down 4-6 times with the smallest fire-polished glass Pasteur pipette. The cell suspension was sedimentated and centrifuged at 1000 rpm for 4 min. Neurobasal plating medium (Gibco, Gaithersburg, MD) containing 10% FBS supplement and 1% L-glutamine were added. Cells were planted onto poly-L-lysine-pretreated 96-well (9 mm) clear-bottomed black plates with a density of 1.2-1.8 3 10 6 cells/well. Cells were incubated at 378C with 5% CO 2 and 95% humidity. Cytosine arabinoside (10 lM) was added to the culture medium on Day 3 after planting to prevent proliferation of non-neuronal cells. The planting medium was replaced on Day 5 with the neurobasal growth medium containing 10% B27, 1% L-glutamine and 1% HEPES. The cells were measured for synchronous Ca 21 oscillations at 9 day in vitro (DIV).
16,17
Compound preparation l-CDL was dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 30 mM. Then diluted the l-CDL with DMSO to give a series of secondary stock solutions of 10, 3, 1 and 0.3 mM. The NMDA receptor agonist NMDA, AMPA receptor agonist AMPA, mGlu1/5 receptor agonist DHPG and l-glutamic acid were dissolved in 0.01 M PBS at a stock concentration of 10, 30 and 5 mM respectively. Before each experiment all compounds above were diluted 125-fold by using Locke's buffer (8.6 mM HEPES, 5.6 mM KCl, 154 mM NaCl, 5.6 mM glucose, 1.0 mM MgCl 2 , 2.3 mM CaCl 2 , 0.0001 mM glycine, pH 7.4). This dilution in Locke's buffer resulted in solutions of the compounds were eight times the desired final concentrations in the assay.
Measurement of intracellular Ca 21 concentration
On Day 9, the culture medium of the cells in the 96-well clear-bottomed black plates was removed and replaced with dye loading buffer (100 ll/well) containing 4 lM fluo-8. After incubation for 1 hr, cells were washed with Locke's buffer for five times using an automated cell washer (BioTek Instruments, Winooski, VT), leaving a final volume of 150 ll in each well. Then the plate was transferred to a fluorescence laser plate reader (Molecular Devices, Sunnyvale, CA) chamber. Fluorescence reading was taken for 5 min to establish the baseline, and then 25 ll of the first test compound solutions (83) were added to corresponding well. After the fluorescence readings were taken for 5 min, 25 ll of the second compounds (83) were added to the cells and the cells were exposed to test compounds for another 10 min.
Background fluorescence was automatically subtracted from all fluo-8 fluorescence measurements.
Western blot
To investigate the expressions of the phosphorylated protein levels of ERK1/2 and PKC g, tissue extracts were analyzed as described before. 18, 19 In brief, tissues (spinal cord segments at L4-L6) were collected and washed with ice-cold PBS before being lysed in RIPA. Then whole lysates containing 50 lg proteins were separated on sodium dodecyl sulfate-polyacrylamide gels, and transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% BSA for 2 hr at room temperature and incubated overnight at 48C with the primary antibodies GAPDH (1:8000), p-PKC (1:1000), p-ERK1/2 (1:1000), PKC (1:1000) and ERK1/2 (1:1000). After then, the membranes were washed with 0.1% TBST and incubated for 2 hr at room temperature with the secondary antibodies (1:3000). Signals were finally detected using ECL reagents (PerkinElmer, Waltham, MA). Data were analyzed with the Molecular Imager (Gel DocTM XR, 170-8170) and the associated software Quantity One-4.6.5 (Bio-Rad Laboratories).
Statistical analysis
SPSS Rel 15 (SPSS, Chicago, IL) and GraphPad Prism software (Version 6.0; GraphPad Software, San Diego, CA) were used to conduct the statistical analyses. Data were statistically evaluated by one-way analysis of variance (ANOVA) and the two-way ANOVA followed by Bonferroni's post-hoc tests.
Results are expressed as mean 6 standard error from three independent experiments in triplicate. Results described as significant were based on a criterion of p < 0.05.
Results
l-CDL attenuates mechanical hypersensitivity in TCI induced bone cancer pain
The radiologic and histologic results showed that the bone was destructed and infiltrated with tumors after the transplantation of Walker 256 cells on Day 14 (Fig. 1a) . The mechanical hypersensitivity was displayed in the rats after the transplantation of Walker 256 cells, which further confirmed that the model was successfully made (Fig. 1b) . However, thermal withdrawal threshold was not changed following the intra-tibial injections of Walker 256 carcinoma cells as revealed by Hargreaves test (Supporting Information Fig. S1 ), 20 which consistent with other reports with the same model. 21, 22 The antinociception test was performed on the 14th day. Single administration of l-CDL (3.75, 7.5, 15, 30 mg/kg, p.o.) significantly attenuated TCI induced mechanical hypersensitivity (Fig. 1c) , consistent administration of l-CDL (3.75, 7.5, 15, 30 mg/kg, p.o.) for 7 days obviously ameliorated TCI induced mechanical hypersensitivity without tolerance and resistance (Fig. 1d ). What's more, as depicted in Figure 1a , bone destruction and tumor infiltration were not changed by l-CDL, which ruled out that l-CDL induced inhibition of bone cancer pain was a result of its anti-cancer effect.
l-CDL induced suppression of the spontaneous Ca 21 oscillations in primary cultures neurons of spinal cord is mediated by glutamate
We next explored the mechanism of l-CDL induced antinociception. As it used to be thought that chronic pain is a reflection of the aberrant excitability of dorsal horn neurons evoked by peripheral sensory inputs. 23 The increased neuronal excitability and spinal synaptic plasticity in rats promote the development of chronic pain. 24 It has been reported that spontaneous Ca 21 transients have been implicated in regulating plasticity in developing neurons. 25 oscillations. 17 We explored whether l-CDL could suppress the neuronal plasticity to attenuate chronic pain. Herein, spinal neurons were cultured in 96-well plates (density of 1. in spinal neurons can drive the spontaneous Ca 21 oscillations. 17 Acute challenge of spinal neurons with L-glutamic acid (5 lM) produced a rapid rise in Ca 21 oscillations (Fig. 2a, To further confirmed that l-CDL exerted antinociception in the spinal cord, l-CDL (7.5, 15, 30 lg/20 ll) was administrated intrathecally to the TCI rats. The results indicated that the mechanical hypersensitivity was notably ameliorated (Fig.  4d) . l-CDL (15 lg/20 ll) induced antinociception was also abolished by intrathecal administration of NMDA (0.05 lg/ 20 ll) and DHPG (1 lg/20 ll; Figs. 4e and 4f), but not AMPA (0.05 lg/20 ll; Fig. 4g ). It should be noted that systemic administration of l-CDL alone (up to 30 mg/kg) showed no notable effects on the motor function in normal rats (Supporting Information Fig. S2 ).
l-CDL reduces TCI-induced phosphorylation of PKC c and ERK1/2 in rat spinal cord
The activation of NMDA and mGlu1/5 receptors can further activate PKC g and ERK1/2 to enhance the excitability of the spinal cord neurons. 29, 30 Both intrathecal administration of PKC inhibitor and negative control of ERK1/2 signaling could attenuate pain. 10, 31 We wondered whether l-CDL inhibited the phosphorylation of PKC g and ERK1/2 to attenuate TCI induced bone cancer pain. Herein, the levels of p-PKC g and p-ERK1/2 were upregulated in the spinal cord of TCI rats. Single administration of l-CDL (7.5, 15, 30 mg/kg, p.o.) significantly reduced TCI induced upregulation of p-PKC g and p-ERK1/2 (Figs. 5a and 5b ). Figs. 6e and 6f) . These results suggested that p-PKC g and p-ERK1/2 were involved in NMDA and mGlu1/5 receptors mediated analgesia of l-CDL.
Discussion
In this study, the principal findings are that: (i) l-CDL can effectively attenuate TCI induced bone cancer pain.
(ii) l-CDL effectively attenuates TCI induced bone cancer pain partly due to the simultaneous inhibition of NMDA and mGlu1/5 receptors and the downstream p-PKC g and p-ERK1/2 signaling in the spinal cord. And simultaneously inhibiting the NMDA and mGlu1/5 receptors may present new mechanism to effectively attenuate bone cancer pain. Bone cancer pain seriously affected patients' quality of life, unfortunately cancer pain is often undertreated. Finding an effective and safe medicine with definite mechanism is crucial for the cancer patients. Corydalis yanhusuo W. T. Wang has been used as one of the primary Chinese antinociceptive herbs for hundreds of years and tetrahydroprotoberberines (THPBs) are the major active ingredient of it. Some of these alkaloids have been used in clinic and have been proved to be safe. 32 l-CDL, a THPB in Corydalis yanhusuo W. T. Wang was found in this report could significantly attenuate bone cancer pain. l-CDL may constitute an effective and safe treatment option for cancer patients experiencing severe pain. The mechanisms of bone cancer pain are complex. It results not only from the tumor itself, but also through direct or indirect tumor induced dysregulation of other factors like central sensitization, which is common in advanced bone cancer pain. 4 Peripheral noxious stimuli induced dysregulation can increase neuronal excitability and plasticity to sensitize central neural structures. 33, 34 35 we explored the hypothesis that the inhibitory effect of l-CDL was mediated by glutamate receptors. Glutamate receptors, including ionotropic (iGlu) and mGlu glutamate receptors, play a crucial role in pain pathways and modulation of glutamate receptors may have potential for therapeutic utility in persistent pain. 6 The iGlu receptors (NMDA, AMPA and Kainate acid receptors) mainly mediate fast synaptic excitability. The mGlu receptors also have three groups, group I (mGlu1 and mGlu5), group II (mGlu2 and mGlu3) and group III (mGlu4, mGlu6, mGlu7 and mGlu8) mainly produce slower synaptic excitability. 36 The group I are excitatory and are believed to act mainly via Gaq proteins and activate PKC, whereas group II and group III inhibit adenylate cylase via Gai and Gbg subunits respectively. 26 Intrathecal administration of NMDA and mGluR1/5 receptor agonist induces hypersensitivity in mice, 37, 38 whereas NMDA and mGluR1/5 receptor antagonist and inhibition of AMPA-receptor expression are reported to attenuate neuropathic pain. [38] [39] [40] Inhibition of NMDA and mGluR1/5 receptors also can attenuate bone cancer pain, 41, 42 but the underlying mechanism need further exploration. Nowadays, only NMDA receptor antagonist has been used in clinical practice, but the channel blockers, such as Ketamine and MK801 (dizocipine) are associated with severe side effects, which limit their clinic use. 6, 27 Our results indicated that l-CDL could inhibit both NMDA and mGlu1/5 receptors to inhibit the excitability of spinal neurons and attenuate bone cancer pain. And l-CDL showed no notable effects on motor depression in normal rats which is usual side effects of NMDA antagonist. 43 The behavior test showed that l-CDL significantly suppressed mechanical hypersensitivity in TCI rats, with the effect lasting for a long time even to 24 hr at dose of 30 mg/kg. This strong analgesic effect may be a result of the co-inhibition of the NMDA and mGlu1/5 receptors. As the previous stated that the NMDA receptors mediate fast synaptic excitability, while mGlu1/5 receptors mediate slower synaptic excitability. Its antinociception may be mainly mediated by NMDA receptors in the earlier stage and in later period, the antinociception may be mainly mediated by mGlu1/5 receptors.
It has been reported that the activation of NMDA and mGlu1/5 receptors can elevate cytosolic Ca 21 in the spinal cord. 9 The increased cytosolic Ca 21 then activate the p-PKC g and p-ERK1/2 to enhance excitability of spinal neurons. What is more, the activated p-PKC g and p-ERK1/2 also in turn leading to the phosphorylation of the NMDA receptor, which initiating prolonged enhancement of the excitability in spinal cord neurons. 44 It has been demonstrated that TCI operation results in a notable increased expression of p-PKC g and p-ERK1/2 in the spinal cord, and inhibition of ERK1/2 activation partly reverses the mechanical hypersensitivity of the TCI rats. 10, 45 Herein, we further observed that l-CDL could decrease the increased expressions of p-PKC g and p-ERK1/2, and the inhibitory effect of l-CDL could be abolished by NMDA and mGlu1/5 receptor agonist in the spinal cord of TCI rats. There results suggested that the PKC g and ERK1/2 may be the downstream effectors of NMDA and mGlu1/5 receptors in l-CDL induced antinociception in the spinal cord of TCI rats.
Our results demonstrated that l-CDL could not inhibit AMPA receptor agonist induced Ca 21 influx in primary cultures neurons of spinal cord. AMPA also could not abolish the antinociception of l-CDL in TCI rats. It is probably because that AMPA receptors mediate most of rapid synaptic excitatory neurotransmission and conduct mainly Na 1 currents and partly Ca 21 currents, while NMDA receptors and mGlu1/5 receptors mainly mediate the Ca 21 currents. 46 In summary, our results indicate that l-CDL, a trace constituent of Corydalis yanhusuo W. T. Wang can effectively attenuate TCI induced bone cancer pain through coinhibiting the NMDA and mGlu1/5 receptors and the downstream PKC g and ERK1/2 without notable side effects. And coinhibition of NMDA and mGlu1/5 receptors in the spinal cord may present new opportunities for treatment and management of bone cancer pain.
